Skip navigation
Search
Sciety application settings
Home
Groups
Explore
Newsletter
About
Log In
Sign Up
PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study
Kunchen Wei
Tiansheng Sun
Xiao Feng
Yang Chen
Qingzhong Liu
Hao Tang
Read the full article
See related articles
Listed in
This article is not in any list yet, why not save it to one of your lists.
Log in to save this article
Abstract
No abstract available
Article activity feed
Version published to 10.1186/s12885-025-13868-9
Mar 12, 2025
Version published to 10.21203/rs.3.rs-5391255/v1 on Research Square
Dec 9, 2024
Related articles
Efficacy Analysis and Prognostic Factors of First-line Chemotherapy Combined with Immunotherapy in Extensive-stage Small Cell Lung Cancer: A Real-world Study
This article has 7 authors:
Jian-Xi Zhou
Yun-Chuan Sun
Li Xiao
Hong-Ling Lu
Xiao-Ming Yin
Kui Fan
Ying-Nan Zhou
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer
This article has 18 authors:
Natalie J. Miller
Christina S. Baik
Joel W. Neal
Fangdi Sun
Rafael Santana-Davila
Sylvia Lee
Keith D. Eaton
Renato G. Martins
Cristina Rodriguez
Heather A. Wakelee
Sukhmani K. Padda
Eric Q. Konnick
Alex Camai
Tatyana Pisarenko
Viswam S. Nair
A. McGarry Houghton
Shin-Heng Chiou
Diane Tseng
The Impact of Age on the Effectiveness of Immune Checkpoint Inhibitors Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
This article has 7 authors:
Yuliia Moskalenko
Oleksandr Yazykov
Olena Vasylieva
Kateryna Smiian
Tetiana Ivakhniuk
Hanna Budko
Roman Moskalenko
Site navigation links
Home
Groups
Explore
Newsletter
About
Log In
Sign Up